Weekly paclitaxel combined with monthly carboplatin in elderly patients with advanced non-small cell lung cancer: A multicenter phase II study

Journal of Thoracic Oncology

Volumn 1, Issue 4, 2006, Pages 328-334

  Pujol, Jean Louis ^a,j   Milleron, Bernard ^b   Molinier, Olivier ^a   Quoix, Elisabeth ^c   Depierre, Alain ^d   Breton, Jean Luc ^e   Gervais, Radj ^f   Debieuvre, Didier ^g   Hominal, Stéphane ^h   Namouni, Fouad ⁱ   Tonelli, Dominique ⁱ  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b HÔPITAL TENON   (France)

^c Strasbourg academic hospital group   (France)

^d Hospital of Besancon   (France)

^e Belfort Hospital   (France)

^f Cancer Institute   (France)

^g Vesoul Hospital   (France)

^h Centre Hospitalier de la Region d'Annecy   (France)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j HÔPITAL ARNAUD DE VILLENEUVE   (France)

more..

Author keywords

Carboplatin; Efficacy safety ratio; Elderly; Non small cell lung cancer; Paclitaxel; Phase II; Quality of life

Indexed keywords

CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; DEXCHLORPHENIRAMINE; PACLITAXEL; RANITIDINE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CYTOPATHOLOGY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; LUNG TUMOR; MORTALITY; PSYCHOLOGICAL ASPECT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PACLITAXEL; QUALITY OF LIFE;

EID: 34247270268     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/s1556-0864(15)31590-2     Document Type: Article

References (31)

1. Fry WA, Menck HR, Winchester DP, et al. The National Cancer Data Base report on lung cancer. Cancer 1996;77:1947-1955.
2. Vercelli M, Capocaccia R, Quaglia A, et al. Relative survival in elderly European cancer patients: evidence for health care inequities. Crit Rev Oncol Hematol 2000;35:161-179.
3. Non-Small Cell Lung Cancer Collaborative Group (NSCLCCG). Chemotherapy in non-small cell lung cancer: a meta-analysis using up-dated data on individual patients of 52 randomized trials. Br Med J 1995;311:899-909.
4. Murphy WK, Fossella FV, Winn RJ, et al. A phase II study of Taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993;85:384-388.
5. Chang AY, Kim K, Glick J, et al. Phase II of Taxol, merbarone and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993;85:388-394.
6. Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst 2000;92:1074-1080.
7. Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 2004;22:3852-3859.
8. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response and survival analysis. J Clin Oncol 1995;13:1860-1870.
9. Johnson DH, Paul DM, Hande KR, et al. Paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase II trial. J Clin Oncol 1996;14:2054-2060.
10. 2) plus carboplatin (6 AUC) in advanced non-small cell lung cancer: a multicenter randomized trial. Ann Oncol 2000;11:799-805.
11. Kelly K, Giarritta S, Akerkey W, et al. Should older patients receive combination chemotherapy for advanced non-small cell lung cancer? An analysis of Southwest Oncology trials 9509 and 9308 (Abstract). Proc Am Soc Clin Oncol 2001;20:1313A.
12. Akerley W. Paclitaxel in advanced non-small cell lung cancer: an alternative high-dose weekly schedule. Chest 2000;117:152S-155S.
13. Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003;21:2933-2939.
14. Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors (Special article). J Natl Cancer Inst 2000;92:205-216.
15. National Cancer Institute: Investigator's Handbook: A Manual for Participants in Clinical Trials of Investigational Agents Sponsored by DCTD, NCI. Bethesda, MD: National Cancer Institute, 1993.
16. Hollen PJ, Gralla RJ, Kris MG, et al. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale. Eur J Cancer 1993;29A(Suppl 1):S51-S58.
17. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled clinical trials. 1989;10:1-10.
18. Hryniuk W, Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990;8:1935-1937.
19. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
20. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372.
21. Ohe Y, Niho S, Kakinuma R, et al. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol 2004;15:45-50.
22. Fabi A, Barduagni M, Ferraresi V, et al. The combination of carboplatin and weekly paclitaxel: a sage and active regimen in advanced non-small cell lung cancer patients - a phase I-II study. J Exp Clin Cancer Res 2004;23:25-32.
23. Hirabayashi M, Endoh K, Teramachi M, et al. Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: a Kansai Clinical Oncology Group Study. Lung Cancer 2004;44:355-362.
24. Jatoi A, Stella PJ, Hillman S, et al. Weekly carboplatin and paclitaxel in elderly non-small cell lung cancer patients (≥ 65 years of age): a phase II North Central Cancer Treatment Group study. Am J Clin Oncol. 2003;26:441-447.
25. Neubauer M, Schwartz J, Caracandas J, et al. Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive non-small cell lung cancer with Eastern Cooperative Oncology Group Performance Status of 2, or age ≥ 70 years. J Clin Oncol 2004;22:1872-1877.
26. Forsyth PA, Balmaceda C, Peterson K, Seidman AD, Brasher P, DeAngelis LM. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol 1997;35:47-53.
27. Lilenbaum RC, Herndon JE List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2006;23:190-196.
28. Kubota K, Furuse K, Kawahara M, et al. Cisplatin-based combination chemotherapy for elderly patients with non-small cell lung cancer. Cancer Chemother Pharmacol 1997;40:469-474.
29. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. Adopted on September 8, 2003, by the American Society of Clinical Oncology. J Clin Oncol 2004;22:330-353.
30. Gralla RJ, Thatcher N. Quality-of-life assessment in advanced lung cancer: considerations for evaluation in patients receiving chemotherapy. Lung Cancer 2004;46(Suppl 2):S41-S47.
31. Colinet B, Jacot W, Bertrand D, et al. A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index. Br J Cancer 2006;93:1098-1105.